samedan logo
 
 
 
spacer
home > pmps > winter 2002 > nasal delivery of vaccines
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Nasal Delivery of Vaccines

The nasal delivery of vaccines has recently emerged as an attractive alternative to injection. Nasal vaccination has the advantage that it elicits both local and systemic immune responses. The mucosal immune response is rapid and nasal vaccines may also induce protection in distant mucosal sites. Correct formulation and adequate distribution to the nasal mucosa are, however, essential for efficacy and safety. The complexity of nasal geometry represents a major challenge for efficient intranasal vaccination, and current delivery devices may prove inadequate in meeting future safety and reliability requirements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Per Gisle Djupesland, Founder, Head of R&D and Chairman of OptiNose AS
Dr Per Gisle Djupesland is Founder, Head of R&D and Chairman of OptiNose AS, a Norwegian R&D company developing devices based on a novel technology for the nasal delivery of drugs and vaccines. Dr Djupesland is a specialist in Otorhinolaryngology.

He has a PhD in Nasal Physiology and Aerodynamics from the University of Oslo and has also been Research Fellow at the University of Toronto, Canada. Dr Djupesland holds a degree in International Health and Tropical Medicine from the University of Pierre and Marie Curie in Paris, France, and has been Project Manager for a large-scale vaccination trial for the Norwegian Armed Forces.

spacer
Dr Per Gisle Djupesland
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was 271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement